Formulary (pharmacy)

RADICAVA ORS® (edaravone) Added to U.S. Department of Veterans Affairs National Formulary

Retrieved on: 
Friday, March 10, 2023

JERSEY CITY, N.J., March 10, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is proud to announce that as of June 2022, RADICAVA ORS® (edaravone) has been added to the U.S. Department of Veterans Affairs National Formulary (VANF), with a national prior authorization process in place, making the treatment accessible to U.S. veterans living with amyotrophic lateral sclerosis (ALS) who are within the VA's integrated healthcare system.

Key Points: 
  • "Given the devastating nature of ALS and the demand for additional treatment options, we are thrilled to see RADICAVA ORS added to the VA's National Formulary," said Atsushi Fujimoto, President, MTPA.
  • "MTPA is committed to helping U.S. veterans living with ALS have access to our treatments, and we applaud the VA for making RADICAVA ORS available as an option for them."
  • The Criteria for Use of RADICAVA ORS can be found at the VA website here: https://www.pbm.va.gov/apps/VANationalFormulary/ .
  • RADICAVA and RADICAVA ORS are contraindicated in people with a history of hypersensitivity to edaravone or any of the inactive ingredients.1 See Important Safety Information below.